Cargando…
An Open‐Label Study to Assess the Effect of Itraconazole and Rifampin on Parsaclisib Pharmacokinetics When Administered Orally in Healthy Participants
Parsaclisib, a selective, potent phosphatidylinositol 3‐kinase delta inhibitor being developed for the treatment of cancer and autoimmune diseases, is primarily metabolized by cytochrome P450 (CYP) 3A4. This study assessed the pharmacokinetics (PK) and safety of parsaclisib alone or combined with it...
Autores principales: | Li, Jia, Rockich, Kevin, Yuska, Brad, Zhou, Gongfu, Epstein, Noam, Punwani, Naresh, Chen, Xuejun, Yeleswaram, Swamy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7586811/ https://www.ncbi.nlm.nih.gov/pubmed/32515832 http://dx.doi.org/10.1002/jcph.1653 |
Ejemplares similares
-
The Effect of Renal Impairment on the Pharmacokinetics and Safety of Itacitinib
por: Srinivas, Nithya, et al.
Publicado: (2020) -
Pharmacokinetics of the Monoclonal Antibody MHAA4549A Administered in Combination With Oseltamivir in Patients Hospitalized With Severe Influenza A Infection
por: Deng, Rong, et al.
Publicado: (2020) -
Evaluation of drug–drug interaction potential for pemigatinib using physiologically based pharmacokinetic modeling
por: Ji, Tao, et al.
Publicado: (2022) -
Population Pharmacokinetics Analysis of Pemigatinib in Patients With Advanced Malignancies
por: Ji, Tao, et al.
Publicado: (2022) -
Effects of rifampin, itraconazole and esomeprazole on the pharmacokinetics of alisertib, an investigational aurora a kinase inhibitor in patients with advanced malignancies
por: Zhou, Xiaofei, et al.
Publicado: (2017)